Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Multiple Sclerosis and SARS-CoV-2 Vaccination: Considerations for Immune-Depleting Therapies
Johann Sellner, Paulus Rommer
Vaccines (2021) Vol. 9, Iss. 2, pp. 99-99
Open Access | Times Cited: 27

Showing 1-25 of 27 citing articles:

Administration of COVID-19 vaccines in immunocompromised patients
Manica Negahdaripour, Mojtaba Shafiekhani, Seyed Mohammad Iman Moezzi, et al.
International Immunopharmacology (2021) Vol. 99, pp. 108021-108021
Open Access | Times Cited: 72
Cladribine Tablets for Relapsing–Remitting Multiple Sclerosis: A Clinician’s Review
Gavin Giovannoni, Joela Mathews
Neurology and Therapy (2022) Vol. 11, Iss. 2, pp. 571-595
Open Access | Times Cited: 40
SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study
Maria Pia Sormani, Irene Schiavetti, Doriana Landi, et al.
Multiple Sclerosis Journal (2021) Vol. 28, Iss. 7, pp. 1034-1040
Open Access | Times Cited: 47
Humoral and Cellular Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients with Multiple Sclerosis: An Israeli Multi-Center Experience Following 3 Vaccine Doses
Ron Milo, Elsebeth Staun-Ram, Dimitrios Karussis, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 35
Vaccination and multiple sclerosis in the era of the COVID-19 pandemic
Tobias Monschein, Hans‐Peter Hartung, Tobias Zrzavy, et al.
Journal of Neurology Neurosurgery & Psychiatry (2021) Vol. 92, Iss. 10, pp. 1033-1043
Open Access | Times Cited: 36
Multiple Sclerosis, Disease-Modifying Therapies and COVID-19: A Systematic Review on Immune Response and Vaccination Recommendations
Verónica Cabreira, Pedro Abreu, Ricardo Soares-dos-Reis, et al.
Vaccines (2021) Vol. 9, Iss. 7, pp. 773-773
Open Access | Times Cited: 32
COVID‐19 vaccination hesitancy among people with chronic neurological disorders: A position paper
Martin Rakuša, Şerefnur Öztürk, Elena Moro, et al.
European Journal of Neurology (2022) Vol. 29, Iss. 8, pp. 2163-2172
Open Access | Times Cited: 23
From diagnosis to treatment: exploring the mechanisms underlying optic neuritis in multiple sclerosis
Bin Tong, Xin Zhang, Haijian Hu, et al.
Journal of Translational Medicine (2025) Vol. 23, Iss. 1
Open Access
COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab
Fabio Buttari, Antonio Bruno, Ettore Dolcetti, et al.
Multiple Sclerosis and Related Disorders (2021) Vol. 52, pp. 102983-102983
Open Access | Times Cited: 30
Humoral response to SARS-CoV-2 COVID-19 vaccines in patients with multiple sclerosis treated with immune reconstitution therapies
Jelena Drulović, Jovana Ivanović, Vanja Martinović, et al.
Multiple Sclerosis and Related Disorders (2021) Vol. 54, pp. 103150-103150
Open Access | Times Cited: 30
Repeated iv anti‐CD20 treatment in multiple sclerosis: Long‐term effects on peripheral immune cell subsets
Julia Feige, Tobias Moser, Katja Akgün, et al.
Annals of Clinical and Translational Neurology (2024) Vol. 11, Iss. 2, pp. 450-465
Open Access | Times Cited: 3
Bruton's Tyrosine Kinase Inhibition in the Treatment of Preclinical Models and Multiple Sclerosis
Anja Steinmaurer, Isabella Wimmer, Thomas Berger, et al.
Current Pharmaceutical Design (2021) Vol. 28, Iss. 6, pp. 437-444
Closed Access | Times Cited: 23
Summary of safety and efficacy of COVID-19 vaccination in patients with multiple sclerosis
Eva Pernicová, Petra Macounová, Martin Krsek, et al.
European Neurology (2023) Vol. 86, Iss. 4, pp. 263-276
Open Access | Times Cited: 9
Multiple Sclerosis Patients and Disease Modifying Therapies: Impact on Immune Responses against COVID-19 and SARS-CoV-2 Vaccination
Maryam Golshani, Jiří Hrdý
Vaccines (2022) Vol. 10, Iss. 2, pp. 279-279
Open Access | Times Cited: 14
Multiple Sclerosis, COVID-19 and Vaccines: Making the Point
Simona Toscano, Clara Grazia Chisari, Francesco Patti
Neurology and Therapy (2021) Vol. 10, Iss. 2, pp. 627-649
Open Access | Times Cited: 13
Diroximel Fumarate as a Novel Oral Immunomodulating Therapy for Relapsing Forms of Multiple Sclerosis: A Review on the Emerging Data
Larissa Hauer, Johann Sellner
Drug Design Development and Therapy (2022) Vol. Volume 16, pp. 3915-3927
Open Access | Times Cited: 9
Multiple sclerosis-disease modifying therapies affect humoral and T-cell response to mRNA COVID-19 vaccine
Federica Dominelli, Maria Antonella Zingaropoli, Matteo Tartaglia, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 9
Alemtuzumab treatment for multiple sclerosis in Austria: An observational long‐term outcome study
Tobias Moser, Fabian Foettinger, Wolfgang Hitzl, et al.
Annals of Clinical and Translational Neurology (2024) Vol. 11, Iss. 6, pp. 1442-1455
Open Access | Times Cited: 1
Envisioning Post-pandemic Digital Neurological, Psychiatric and Mental Health Care
Amit Khanna, Graham B. Jones
Frontiers in Digital Health (2021) Vol. 3
Open Access | Times Cited: 10
Cladribine Tablets Mode of Action, Learning from the Pandemic: A Narrative Review
Federico Carlini, Valeria Lusi, Caterina Rizzi, et al.
Neurology and Therapy (2023) Vol. 12, Iss. 5, pp. 1477-1490
Open Access | Times Cited: 2
Die Corona-Pandemie und Multiple Sklerose: Impfungen und deren Implikationen für Patienten – Teil 1: Empfehlungen
Tobias Monschein, Tobias Zrzavy, Micha Löbermann, et al.
Der Nervenarzt (2021) Vol. 92, Iss. 12, pp. 1276-1282
Open Access | Times Cited: 5
Literaturverzeichnis zum Titel: Zettl/Sieb: Diagnostik und Therapie neurologischer Erkrankungen, 6.A. 2024

Elsevier eBooks (2024), pp. e1-e123
Closed Access
Immunmediierte Erkrankungen des Nervensystems
Uwe K. Zettl, Jörn Peter Sieb
Elsevier eBooks (2024), pp. 47-109
Closed Access
Safety of pathogenetic therapy for multiple sclerosis during the COVID-19 pandemic
А. М. Петров, М. В. Вотинцева, I. D. Stolyarov
Annals of Clinical and Experimental Neurology (2022) Vol. 16, Iss. 2, pp. 70-77
Open Access | Times Cited: 1
COVID-19 vaccination guidelines for patients with multiple sclerosis
Н В Хачанова, N. А. Totolyan, Ya. V. Vlasov, et al.
Neurology neuropsychiatry Psychosomatics (2021) Vol. 13, Iss. 2, pp. 157-161
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top